Market research
ADMP Adamis Pharma
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- 0.0%
- Beta
- 1.28
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 0.42
- Dividend yield
- 0.0%
- Beta
- 1.28
About
About Adamis Pharma
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
Research context
Adamis Pharma appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ADMP discussion.
5 years, 6 months ago
Adamis Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 20.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Adamis Pharmaceuticals Corporation's total revenue sank by 27.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 6.9% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 33.4% to $-6M since the same quarter in the previous year.
Based on the above factors, Adamis Pharmaceuticals Corporation gets an overall score of 2/5.